DelveInsight’s “Iris Melanoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Iris Melanoma, historical and forecasted epidemiology as well as the Iris Melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Iris Melanoma Overview
Iris melanoma is part of the group of uveal tumors, which make up one of the most common eye tumors. These arise from the pigmented tissue inside the eye called the uvea. Iris melanomas are the least common among this type of tumour, comprising 4-5 per hundred uveal tumors. The uvea consists of the iris, ciliary muscle, and choroid. The iris is composed of circular and longitudinal layers of muscle that surround a central opening called the pupil. This aperture is crucial in regulating the amount of light that enters the eye. While the circular muscle contraction tightens the opening, the longitudinal muscle layer dilates it in dim light. The iris gets its vast range of coloration from the pigment called melanin, which is present in specialized pigment-producing cells called melanocytes. It is these cells that give rise to the tumor called melanoma.
Iris Melanoma Epidemiology Insights
Iris melanomas are more indolent and exhibit a lower metastasis rate than their ciliary body or choroidal counterparts. The rate of metastasis is approximately 3% at 5 years, 5% at 10 years, and 10% at 20 years. Many patients will develop glaucoma after treatment with brachytherapy and may need to be co-managed with a glaucoma specialist. Pressure lowering drops and CPC is recommended before any intraocular surgery (trabeculectomy and shunt tubes) after treatment of iris melanomas.
As per a study, 2166 cases of uveal melanoma represent 5.4% of all cases of melanoma. Histological confirmation of uveal melanoma was available in all cases. A higher prevalence of 1139 cases (52.6%) in women than 1027 cases (47.4%) in men was observed. Age distribution revealed 1411 cases (65.1%) in the group between 41 and 69 years old. A total of 429 (19.8%) patients were classified as an initial disease and 334 (15.4%) as advanced (regional or distant metastases). Staging as the initial disease was more frequent (113–24.8%) in patients with > 8 school years than in patients with < 8 school years (179–17.6%), reflecting disparities in healthcare access between those two population
Click here to learn more about the Iris Melanoma Market Landscape
The Report Covers the Iris Melanoma Epidemiology Segmented by:
Total Iris Melanoma incident cases
Total Iris Melanoma prevalent cases
Total Iris Melanoma treatment cases
Total Iris Melanoma diagnostic cases
Iris Melanoma Market Outlook
The Iris Melanoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Iris Melanoma market trends by analyzing the impact of current Iris Melanoma therapies on the market, Iris Melanoma unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Iris Melanoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Iris Melanoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Iris Melanoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Iris Melanoma Market
Bristol Myers Squibb
Pfizer
Delcath System Inc
And many others
Iris Melanoma Therapies Covered and Analyzed in the Report:-
Cyclophosphamide
Fludarabine
Sunitinib
And many others
Learn more about the Key Companies and Emerging Therapies in the Iris Melanoma Market.
Table of Contents
Key Insights
Iris Melanoma Introduction
Executive Summary of Iris Melanoma
Disease Background and Overview
Epidemiology and patient population
Iris Melanoma Emerging Therapies
Iris Melanoma Market Outlook
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Iris Melanoma Market Outlook.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting